The office of Dr. Eric Seaman has become the first site in New Jersey for a new test for male fertility called a “CAP-score” made by the privately held company, Androvia.
The limitations of the predictive ability of a semen analysis are well recognized since the test literally relies on “looking” at sperm. Semen analysis relies on measurements of count, motility and shape a proxies for fertilizing ability. But those aren’t actually tests of sperm function at all.
The Androvia test is a readily performed measure of the “capacitation” ability of the sperm. “Capacitation” refers to maturational changes a sperm MUST undergo in order to penetrate and fertilize an egg.
Dr. Seaman’s office was involved with some of Androvia’s initial research and aided in their ability to define CAP-score results for a normal vs. an infertile population. Initially the test will be offered at a significantly discounted fee for the first 50 specimen and tests are currently limited to 2 specimens a week and only on Thursdays. People who are interested must be a patient of Dr. Seaman’s. The test cannot be performed on patients with a severely low sperm count or density below 3Million/ml. It is hoped that new technology such as the cap score can offer new guidance in couples with male factor infertility. For more information visit http://www.androvialifesciences.com/cap-score-sperm-function-test.